If you liked this article you might like

Lack of Catalysts Keeps Analysts Away From Pfizer
Read Scraps Pfizer Break-Up as Megadeals Escape Its Grasp
Allergan's Dealmaking Continues With Vitae Takeout
Will Pfizer Book Another Healthy Quarter?